Copilot
Your everyday AI companion
About 568,000 results
Open links in new tab
  2. People also ask
    Is KRAS a cancer drug?
    Targeting KRAS function is a primary focus of cancer drug discovery. However, currently approved treatments can only address one of many KRAS gene mutations, called G12C, leaving more than half of patients with cancers driven by KRAS without a targeted treatment option.

    Small-molecule drug shows potential for hard to treat cancers

    msn.com
    Why is KRAS important?
    KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide. It plays a crucial role in tumor growth, as it is important for driving uncontrolled proliferation of tumor cells. Targeting KRAS function is a primary focus of cancer drug discovery.

    Small-molecule drug shows potential for hard to treat cancers

    msn.com
    What are KRAS mutations?
    KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers. While a number of KRAS programs are focused on a single mutation, our program is uniquely suited to target the most prevalent KRAS mutations of these cancers in a single therapy,” said Mark Winderlich, PhD, Chief Research & Development Officer.

    HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

    markets.businessinsider.com
    Can hb-700 be used to treat KRAS mutated cancers?
    “HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers.

    HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

    markets.businessinsider.com
    Feedback
  3. ScienceDaily
    https://www.sciencedaily.com/releases/2024/09/240923121349.htm

    Potential breakthrough for hard to treat cancers | ScienceDaily

  4. Technology Networks
    https://www.technologynetworks.com/analysis/news/...

    Small-Molecule Drug Shows Potential for Hard-To-Treat Cancers

    Tags:
    Targeting
    Potential
  5. News-Medical.net
    https://www.news-medical.net/news/2…

    ACBI3 molecule offers new hope for targeting KRAS …

    WEB2 days ago · ACBI3 molecule offers new hope for targeting KRAS mutations in cancer. KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of …

    Tags:
    Targeting
    Molecule
  6. Markets Insider
    https://markets.businessinsider.com/news/stocks/...

    Medigene AG Expands Protection of its KRAS Library with Filing of …

  7. OncLive
    https://www.onclive.com/view/loder-plus-soc...

    LODER Plus SOC Chemotherapy Elicits Responses, Boosts OS in …

    Tags:
    Pancreatic cancer
    Local property
  8. Targeted Oncology
    https://www.targetedonc.com/view/targeted-pulse-september-22

    The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KRAS …

    Tags:
    Renal cell carcinoma
    Nivolumab
  9. Science | AAAS
    https://www.science.org/doi/10.1126/scienc…

    KRAS takes the road to destruction | Science - AAAS

    WEB6 days ago · KRAS takes the road to destruction. Mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog) gene are a major driver of cancer development and metastatic growth. Once considered …

  10. Science | AAAS
    https://www.science.org/doi/10.1126/scienc…

    Targeting cancer with small-molecule pan-KRAS …

    WEB6 days ago · Kirsten rat sarcoma virus (KRAS) is a frequently mutated oncogene in human cancer. Targeting KRAS function is a high priority for cancer drug development, and in recent years, drugs that inhibit the …

    Tags:
    Targeting
    Science
  11. Nature
    https://www.nature.com/articles/s41467-024-51828-2

    RAS-ON inhibition overcomes clinical resistance to KRAS G12C

  12. Chemical & Engineering News
    https://cen.acs.org/pharmaceuticals/dru…

    Degrader takes out many forms of KRas - Chemical

    WEB2 days ago · The enzyme KRas has become a popular cancer target for drugmakers in the last decade, with many companies developing small molecules that inhibit one or multiple KRas mutants. Now, scientists are ...

  14. Some results have been removed